155 related articles for article (PubMed ID: 15073032)
1. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
Lenihan DJ; Alencar AJ; Yang D; Kurzrock R; Keating MJ; Duvic M
Blood; 2004 Aug; 104(3):655-8. PubMed ID: 15073032
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.
Lundin J; Hagberg H; Repp R; Cavallin-Ståhl E; Fredén S; Juliusson G; Rosenblad E; Tjønnfjord G; Wiklund T; Osterborg A
Blood; 2003 Jun; 101(11):4267-72. PubMed ID: 12543862
[TBL] [Abstract][Full Text] [Related]
3. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome.
Lundin J; Kennedy B; Dearden C; Dyer MJ; Osterborg A
Blood; 2005 May; 105(10):4148-9. PubMed ID: 15867423
[No Abstract] [Full Text] [Related]
4. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab.
Kennedy GA; Seymour JF; Wolf M; Januszewicz H; Davison J; McCormack C; Ryan G; Prince HM
Eur J Haematol; 2003 Oct; 71(4):250-6. PubMed ID: 12950233
[TBL] [Abstract][Full Text] [Related]
5. Cardiac involvement with mycosis fungoides: could this explain alemtuzumab toxicity?
Sleigh KA; Smith ME; Rule SA
Leuk Lymphoma; 2008 Oct; 49(10):2022-4. PubMed ID: 18452071
[No Abstract] [Full Text] [Related]
6. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
Querfeld C; Mehta N; Rosen ST; Guitart J; Rademaker A; Gerami P; Kuzel TM
Leuk Lymphoma; 2009 Dec; 50(12):1969-76. PubMed ID: 19860617
[TBL] [Abstract][Full Text] [Related]
7. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.
Capalbo S; Delia M; Dargenio M; Liso A; Diomede D; Garofalo L; Liso V
Med Oncol; 2003; 20(4):389-96. PubMed ID: 14716037
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab in Sézary syndrome: efficient but not innocent.
Ure UB; Ar MC; Salihoglu A; Guner SI; Baran A; Oguz O; Ferhanoglu B
Eur J Dermatol; 2007; 17(6):525-9. PubMed ID: 17951134
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab treatment for Sézary syndrome: A single-center experience.
Novelli S; García-Muret P; Sierra J; Briones J
J Dermatolog Treat; 2016; 27(2):179-81. PubMed ID: 26329989
[TBL] [Abstract][Full Text] [Related]
10. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients.
Bernengo MG; Quaglino P; Comessatti A; Ortoncelli M; Novelli M; Lisa F; Fierro MT
Haematologica; 2007 Jun; 92(6):784-94. PubMed ID: 17550851
[TBL] [Abstract][Full Text] [Related]
11. Transformation of Sézary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity.
Nevet MJ; Zuckerman T; Sahar D; Bergman R
Am J Dermatopathol; 2015 Jan; 37(1):73-7. PubMed ID: 25548993
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy.
Vaughan J; Harrington AM; Hari PN; Kroft SH; Olteanu H
Am J Clin Pathol; 2012 Mar; 137(3):403-11. PubMed ID: 22338052
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
Gautschi O; Blumenthal N; Streit M; Solenthaler M; Hunziker T; Zenhäusern R
Eur J Haematol; 2004 Jan; 72(1):61-3. PubMed ID: 14962265
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review.
Stewart JR; Desai N; Rizvi S; Zhu H; Goff HW
Eur J Dermatol; 2018 Dec; 28(6):764-774. PubMed ID: 30591425
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Sézary Syndrome With Alemtuzumab: A Series of 5 Cases and a Review of the Literature.
del Alcázar-Viladomiu E; Tuneu-Valls A; López-Pestaña A; Vidal-Manceñido MJ
Actas Dermosifiliogr; 2015 Sep; 106(7):e33-9. PubMed ID: 25960287
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly.
Alinari L; Geskin L; Grady T; Baiocchi RA; Bechtel MA; Porcu P
Leuk Res; 2008 Aug; 32(8):1299-303. PubMed ID: 18096224
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab-resistant Sézary syndrome responding to zanolimumab.
Alexandroff AB; Shpadaruk V; Bamford WM; Kennedy DB; Burd R; Dyer MJ
Br J Haematol; 2011 Aug; 154(3):419-21. PubMed ID: 21480857
[No Abstract] [Full Text] [Related]
18. Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review.
Jfri A; Smith JS; Larocca C
J Am Acad Dermatol; 2023 May; 88(5):1164-1166. PubMed ID: 36481378
[No Abstract] [Full Text] [Related]
19. Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy.
Bolli N; Di Ianni M; Simonetti S; Cerroni L; Liso A; Falini B; Tabilio A
Lancet Oncol; 2004 Jan; 5(1):64-5. PubMed ID: 14700612
[No Abstract] [Full Text] [Related]
20. Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab.
Weder P; Anliker M; Itin P; Bargetzi M
Dermatology; 2004; 208(3):281-3. PubMed ID: 15118391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]